OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PRTA
Prothena Corporation plc
There isn't enough reported data to score PRTA yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
PRTA's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PRTA PE Valuation
PRTA has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRTA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PRTA on earnings quality, reporting a profit while its opponent remains loss making.
PRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.47 | +$4.72 |
| Q2 2026 | -$0.83 | +$4.78 |
| Q1 2026 | -$2.81 | -$0.76 |
| Q4 2025 | -$4.53 | -$2.26 |
| Q3 2025 | -$5.19 | -$2.75 |
| Q2 2025 | -$5.61 | -$4.65 |
| Q1 2025 | -$2.05 | +$1.16 |
| Q4 2024 | -$2.27 | +$0.49 |
PRTA is still losing money, but far less than before: $0.47 per share over the past year, against $5.61 at its worst in mid-2025.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PRTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PRTA on profitability, with a higher operating margin.
PRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $620K | -74% |
| Q2 2026 | $1M | -77% |
| Q1 2026 | $51.1M | +1706% |
| Q4 2025 | $21K | -99% |
| Q3 2025 | $2.4M | +149% |
| Q2 2025 | $4.4M | -97% |
| Q1 2025 | $2.8M | +5556% |
| Q4 2024 | $2.1M | +572% |
PRTA's revenue is growing: $620,000 last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3036% | -1369 points |
| Q2 2026 | -2089% | -175 points |
| Q1 2026 | 59% | +2378 points |
| Q4 2025 | -115252% | -112196 points |
| Q3 2025 | -1666% | +5191 points |
| Q2 2025 | -1914% | -1959 points |
| Q1 2025 | -2319% | +160737 points |
| Q4 2024 | -3057% | +21790 points |
PRTA's operating margin was −3036% last quarter, down 1369 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PRTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12M | +$28.6M |
| Q2 2026 | -$25M | +$21.3M |
| Q1 2026 | $28.9M | +$82.2M |
| Q4 2025 | -$23.3M | +$24.5M |
| Q3 2025 | -$40.6M | +$4.6M |
| Q2 2025 | -$46.3M | -390% |
| Q1 2025 | -$53.4M | +$19.7M |
| Q4 2024 | -$47.8M | +$3.3M |
PRTA has burned cash in most quarters: −$31M over the past year, against −$188M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -708K shares |
| 1 year | -4.4% | -2.4M shares |
| 3 years | -11% | -6.6M shares |
| 5 years | +0.5% | +232K shares |
| Available history | +29% | +11.6M shares |
PRTA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | $15.6M |
| Q1 2026 | $6.9M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -8.1x | Net Cash |
| Q4 2021 | -7.9x | Net Cash |
| Q3 2021 | -7.9x | Net Cash |
PRTA has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 20.5 | Neutral |
PRTA's weekly RSI is 44 (neutral) and its Stochastic is 21 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRTA PE vs Healthcare Sector
| Metric | PRTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRTA has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PRTA on trend strength, trading above more of its moving averages.
PRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.34 | 1.3% below |
| 20 week MA | $8.74 | 5.8% below |
| 50 week MA | $9.26 | 11% below |
| 100 week MA | $9.67 | 15% below |
| 200 week MA | $23.8 | 65% below |
PRTA is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PRTA on returns for 2026, with the stronger performance.
PRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $13.2 | -17% |
| 2021 | $13.2 | $48.4 | +265% |
| 2022 | $48.4 | $57.8 | +19% |
| 2023 | $57.8 | $36.3 | -37% |
| 2024 | $36.3 | $15.1 | -58% |
| 2025 | $15.1 | $9.54 | -37% |
| 2026 YTD | $9.54 | $8.23 | -14% |
PRTA has finished three years in a row lower, and it's down 14% so far in 2026.